[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570949":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":34,"centralContacts":39,"locations":49,"responsibleParty":79,"collaborators":10,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":10,"enrollmentInfo":90,"targetDuration":10,"studyType":93,"phases":10,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":52,"whyStopped":10,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Hospices Civils de Lyon","OTHER",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A",null,"Patients with symptomatic severe aortic stenosis, with indication for TAVI. They are followed at inclusion, during hospitalisation of the TAVI procedure, at 1-month follow-up, at 1-year follow-up and by phone at 2 years follow-up.",[13,14],"Biological: Biocollection","Behavioral: Quality of life questionnaires",{"label":16,"type":10,"description":17,"interventionNames":18},"Group B","Patients with asymptomatic severe aortic stenosis, without indication for TAVI. They are followed at inclusion, at 1-month follow-up, at 1-year follow-up and at 2 years follow-up.",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Group C","Patients with asymptomatic middle aortic stenosis, without indication for TAVI. They are followed at inclusion, at 1-month follow-up, at 1-year follow-up and at 2 years follow-up.",[13,14],[24,29],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"BIOLOGICAL","Biocollection","At each sampling time, 2 dry tubes of 4 ml, 1 EDTA tube of 4 ml, and 1 heparinised tube of 4 ml, i.e. a total of 16 ml per sampling time.\n\nGroup A patients will be sampled at inclusion (or before the TAVI procedure), during and after the TAVI procedure, at 1 month follow-up and at 1 year follow-up, for a total of 120 ml. Patients in groups B and C will be sampled at inclusion, 1 month follow-up, 1 year follow-up and 2 years follow-up, for a total of 80 ml.",[9,16,20],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"BEHAVIORAL","Quality of life questionnaires","EQ-5D-5L and HAD questionnaire at inclusion, 1 month follow-up, 1 year follow-up and 2 years follow-up",[9,16,20],[35],{"name":36,"affiliation":37,"role":38},"Ahmad HAYEK, MD","Plateau technique interventionnel - Hôpital Louis Pradel, GHE","PRINCIPAL_INVESTIGATOR",[40,45],{"name":36,"role":41,"phone":42,"phoneExt":43,"email":44},"CONTACT","4 72 35 72 80","+33","ahmad.hayek@chu-lyon.fr",{"name":46,"role":41,"phone":47,"phoneExt":43,"email":48},"Yvonne VARILLON","4 72 35 69 64","yvonne.varillon@chu-lyon.fr",[50,69],{"facility":51,"status":52,"city":53,"state":10,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Hospices Civils de Lyon - Hôpital Croix Rousse","RECRUITING","Lyon","69004","France","FR",{"type":58,"coordinates":59},"Point",[60,61],4.84789,45.74906,{"lat":61,"lon":60},[64,68],{"name":65,"role":41,"phone":66,"phoneExt":43,"email":67},"Brahim Harbaoui, Prof","04 72 35 58 25","brahim.harbaoui@chu-lyon.fr",{"name":65,"role":38,"phone":10,"phoneExt":10,"email":10},{"facility":70,"status":52,"city":53,"state":10,"zip":71,"country":55,"countryCode":56,"cosmosGeoPoint":72,"geoPoint":74,"contacts":75},"Hospices Civils de Lyon - Hôpital Louis Pradel","69500",{"type":58,"coordinates":73},[60,61],{"lat":61,"lon":60},[76,78],{"name":36,"role":41,"phone":77,"phoneExt":43,"email":44},"04 72 35 72 80",{"name":36,"role":38,"phone":10,"phoneExt":10,"email":10},{"type":80,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100570949","identifying-biological-markers-of-cardiovascular-events-in-patients-with-aortic-stenosis-or-tavi-100570949",false,"NCT06713889","Identifying Biological Markers of Cardiovascular Events in Patients With Aortic Stenosis or TAVI","Bio-TAVI","Inclusion Criteria:\n\n* Patients \\>=18 years of age\n* Patient with symptomatic or asymptomatic severe or moderately severe aortic stenosis (according to the recommendations of the European Society of Cardiology - ESC).\n* No opposition.\n\nExclusion Criteria:\n\n* Conjunctive heart disease (e.g. amyloidosis).\n* Presence of a contraindication to TAVI.\n* Impossibility of giving the subject informed information.\n* Privation of civil rights (curatorship, tutorship, protection of justice).","ALL","18 Years",{"count":91,"type":92},125,"ESTIMATED","OBSERVATIONAL","Aortic stenosis, a common cardiovascular disease, is pathophysiologically associated with a chronic inflammatory myocardial reaction and fibrosis leading to cardiac dysfunction and impaired coronary perfusion. These elements may precede the onset of symptoms. The assessment of inflammatory and fibrosis factors (in particular by means of biomarkers) in patients with aortic stenosis will make it possible to identify asymptomatic patients at greater risk who could benefit from intervention earlier. This is part of a personalised medicine adapted to the patient.\n\nPatients will be recruited during their TAVI (Transcatheter Aortic Valve Implantation) assessment consultation. If the patient agrees to take part in the study, information relating to routine care procedures will be collected (patient history, clinical examinations, electrocardiogram, echography, coronary angiography, TAVI procedure if applicable, biology).\n\nOutside of routine care, a biocollection will be established (serum, plasma), quality of life questionnaires will be carried out and adverse events will be collected where present.\n\nPatients will be divided into 3 groups according to the indication for TAVI (Group A - symptomatic severe aortic stenosis with indication for TAVI, Group B - asymptomatic severe aortic stenosis without indication for TAVI, Group C - asymptomatic moderate aortic stenosis without indication for TAVI).\n\nThe main objective is to compare the levels of biomarkers of inflammation and fibrosis between the 3 groups at each sampling time common to all three groups between inclusion and 1-year follow-up.",[96],"Aortic Stenosis",[98,99,100,101],"Aortic stenosis","TAVI","Cardiology","Biomarkers","2026-05-22",{"date":104,"type":105},"2026-05-27","ACTUAL",{"date":107,"type":105},"2024-12-19",{"date":109,"type":92},"2030-06",{"name":5,"class":6},2]